BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medilink Midlands - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medilink Midlands
X-ORIGINAL-URL:https://staging.medilinkmidlands.com
X-WR-CALDESC:Events for Medilink Midlands
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20171029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20170221T080000
DTEND;TZID=Europe/London:20170221T170000
DTSTAMP:20260421T123435
CREATED:20171013T133200Z
LAST-MODIFIED:20171013T133200Z
UID:17658-1487664000-1487696400@staging.medilinkmidlands.com
SUMMARY:Accelerating Clinical Development from First-in-Human to Proof-of-Concept
DESCRIPTION:This seminar will describe how Quotient Clinical’s unique Enabled-First-in-Human® programs significantly reduce the time and cost required to transition to Proof of Concept.  The integration of real-time GMP manufacture and clinical testing minimises CMC investments and simplifies supply chains.  By enhancing the design and speed of early phase clinical programs\, the pressure on R&D budgets is reduced and critical decisions are made sooner. \nPresentation 1: First-in-Human to Proof-of-Concept – there is a better way! \nAlyson Connor\, Executive Director Exploratory Clinical Pharmacology \nA current perspective on the conduct of First-in-Human (FIH) programs in the UK will be shared\, highlighting the benefits of Quotient’s innovative approach.  Case studies will illustrate successes across a range of molecule classes and indications. \nPresentation 2: Adaptive CMC strategies for First in Human programs \nNikki Whitfield\, Vice President\, Pharmaceutical Sciences \nInsights into novel approaches for the development of fit-for-purpose FIH drug products to allow rapid entry into clinic will be described.  Proven strategies for a time- and cost-efficient transition\, within the FIH programme\, to a product suitable for downstream development will be presented. \nTo register your place\, please email Ciaran Flanagan. \nThis event is also taking place in London on Friday 3 March. To go to the event page\, please click here.
URL:https://staging.medilinkmidlands.com/event/accelerating-clinical-development-from-first-in-human-to-proof-of-concept/
LOCATION:Cambridge Building\, Babraham Research Campus\, Cambridge\, CB22 3AT
END:VEVENT
END:VCALENDAR